Unavailable
Unavailable
Save time and jump to the most important pieces.
8-K - PMGC Holdings Inc. (0001840563) (Filer)
SCHEDULE 13G/A - PMGC Holdings Inc. (0001840563) (Subject)
SCHEDULE 13G/A - PMGC Holdings Inc. (0001840563) (Subject)
Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
Northstrive Biosciences Inc. ("Northstrive Biosciences") has submitted a pre-Investigational New Drug ("pre-IND") meeting request to the U.S. Food and Drug Administration ("FDA") for EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments.A pre-IND meeting with the FDA is expected in Q2 2025 to discuss nonclinical studies and Northstrive Biosciences' clinical development plans for EL-22 administered in combination with GLP-1 receptor agonists being used in obese patients. NEWPORT BEACH, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC," "we," or "our"), announced the submiss
Lead asset EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.Northstrive Biosciences Inc. is preparing the necessary steps to leverage existing EL-22 animal data and human safety studies from Korean licensing partner to arrange an Investigational New Drug filing with the U.S. Food and Drug Administration.EL-32 is a pre-clinical, engineered probiotic expressing dual myostatin & activin-A, focusing on two clinically validated targets that play an important role in regulating muscle. NEWPORT BEACH, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Bios
NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC") (NASDAQ:ELAB) is pleased to announce that its operating investment division, PMGC Capital LLC, has begun building its portfolio with strategic investments in the fire prevention technology and the U.S. uranium energy market. These initial investments underscore the Company's commitment to financing innovation in essential industries with significant growth opportunities. Addressing Critical Needs in Energy Security and Fire Prevention PMGC's investments reflect management's belief in the growing demand for both sustainable energy solutions and innovative fire prevention technologies. PMG
3/A - Elevai Labs Inc. (0001840563) (Issuer)
3/A - Elevai Labs Inc. (0001840563) (Issuer)
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical